The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.
about
Primary treatment of Crohn’s disease: combined antibiotics taking center stageStructural brain lesions in inflammatory bowel diseaseCharacterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveysInfliximab-Related Infusion Reactions: Systematic ReviewMultiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!Multifocal Colonic Wall Abscesses during Anti-Tumor Necrosis Factor (TNF)-α Therapy for a Patient with Ulcerative Colitis: A Very Rare Manifestation of Infectious Complications.Biological treatment of Crohn's disease.The safety of infliximab infusions in the community settingNeurological disorders and inflammatory bowel diseasesUpdate on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patientsSerious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.CNS Demyelination with TNF-α BlockersEfficacy and safety of drugs for ulcerative colitis.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.TNF-α inhibitors: are they carcinogenic?Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors.The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics.Lymphoma in inflammatory bowel disease and treatment decisions.Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy.Targeting TNF-α for the treatment of inflammatory bowel disease.Inflammatory bowel disease and demyelination: more than just a coincidence?Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies.Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.Dose escalation of biologics in Crohn's disease: critical review of observational studies.Case report of transverse myelitis in a patient receiving etanercept for rheumatoid arthritis.Value of mucosal assessment and biomarkers in inflammatory bowel disease.Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011?Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α TherapySafety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases.Serum sickness-like disease after switching to biosimilar infliximab.Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.Development of communicating hydrocephalus after infliximab infusion.Pulmonary manifestations of inflammatory bowel disease.
P2860
Q22241483-D8A4E951-5CDF-436F-9A8E-31E02BDE3781Q26776172-3097223A-D523-42FE-BB8B-0BF63EE86983Q26862821-005FF982-2A72-4F7D-A17F-8BCCB8569EBCQ27013835-9EDBE75D-FF0A-42EE-9BF7-ADCC9AB34543Q30571620-3B463EC5-651F-49FA-AF72-E7419BBFCF2FQ32182441-B10DBA86-5D32-430B-A856-6750597B6E00Q33354991-EAD1C09E-809F-4CFC-BF67-9074C19A5E78Q33916750-C0C60776-5650-47E5-8387-8E8BE392C6FFQ33958822-887C6DA1-2871-45E0-A71D-0C35071AD593Q34078707-DB11B223-3EF6-41EC-A173-5305656F3F0BQ35811221-4246EAB8-12A7-4191-A0EF-E529306E929AQ36223905-D3DFD80B-4255-483A-BF15-2FE9CF90777DQ37719132-0EB9D0CC-7D3F-46A9-84C6-C8FBDDFB35D3Q37727232-E2BF19F7-CCD6-4319-8F45-9A3FED20B63AQ37814549-742D5006-4220-48C5-A9A6-A7C32DF8F75CQ37853354-348C106D-90CF-48CE-B3F3-9549075047FEQ37893973-3C035BEB-A845-4022-BECB-D3665884CE15Q37911726-5B710D08-9E69-4B12-BE5D-9F0425C2071DQ37918330-50ED19EA-62E4-4839-9FA4-6FFB8153CE84Q38007126-AC1009C0-B2CB-472B-A87E-4777BD520224Q38024070-08C5DA31-1DD2-48F7-B676-5293729B35EDQ38108468-8327C5F0-9273-4053-8C35-B27148BCEB76Q38160905-A1F2919C-04A2-4192-BF43-17F5F219A974Q38184633-481CF818-A395-4921-B072-7E827A2CF22BQ38202541-EC295730-5B54-477D-98BD-AB58EA3EE01CQ38707864-2F08EE84-DEF3-42C6-A9C2-51E506A9F8DAQ38751610-EB54BFF4-4117-489B-8021-8674B667206AQ38919270-412E8A6F-0E3A-473C-9F98-BF38CA90D0CEQ39223252-46793D4C-6E1D-49CA-BDE3-364BD838FF6DQ39326057-E42FEA00-185E-4316-9BEF-DBFADA6DA0D4Q39557960-41803DD2-461A-48B5-A536-87D821D7B93DQ39866439-CD6F6436-6B84-4EC7-A5C2-D07F638A1491Q40046590-0BA22F32-B42A-4BF5-BEB4-D344E45C490AQ41060236-E17B30F0-8EE2-4A07-865C-AD20079FA3AFQ42078784-A0238D92-ABEA-436B-A300-2759B8364975Q45368191-4FD1BC59-2C27-4A38-86EE-74F5E178E45AQ49608190-03D5EEA0-64C5-4250-B7F0-E11E66B0DEB1Q51036254-68961147-E653-44D3-9F08-71B29F1F4B1DQ53272025-727396A7-27F0-4369-816D-26802BCCB989Q54102332-28D17E36-7C91-4CCA-8480-198CF4EDEE79
P2860
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The safety profile of anti-tum ...... f 620 patient-years follow-up.
@en
The safety profile of anti-tum ...... f 620 patient-years follow-up.
@nl
type
label
The safety profile of anti-tum ...... f 620 patient-years follow-up.
@en
The safety profile of anti-tum ...... f 620 patient-years follow-up.
@nl
prefLabel
The safety profile of anti-tum ...... f 620 patient-years follow-up.
@en
The safety profile of anti-tum ...... f 620 patient-years follow-up.
@nl
P2093
P921
P1476
The safety profile of anti-tum ...... of 620 patient-years follow-up
@en
P2093
A I Thompson
C J Cochrane
D C Wilson
I D Penman
I D R Arnott
J Satsangi
P304
P356
10.1111/J.1365-2036.2008.03882.X
P407
P577
2009-02-01T00:00:00Z